[P26-7] P26-7: Oncologic drugs (3): Pharmaometrics, PK/PD, special population

[P26-7-5] Assessment of sorafenib-induced toxicities and clinical outcomes based on therapeutic drug monitoring of soarfenib for patients with hepatocellular carcinoma

Satoshi Noda¹, Makoto Shioya², Hiroya Iida³, Shigeyuki Naka⁴, Daiki Hira⁵, Akira Andoh⁶, Masaji Tani⁷, Shin-Ya Morita⁸, Tomohiro Terada⁹ (1.Shiga University of Medical Science Hospital, 2.Shiga University of Medical Science Hospital, 3.Shiga University of Medical Science Hospital, 4.Shiga University of Medical Science Hospital, 5.Shiga University of Medical Science Hospital, 6.Shiga University of Medical Science Hospital, 7.Shiga University of Medical Science Hospital, 8.Shiga University of Medical Science Hospital, 9.Shiga University of Medical Science Hospital)

Keywords:Sorafeinb, pharmacokinetics, hepatocellular carcinoma therapeutic drug monitoring